Article
Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.
Virology - 5 Dec 1999
Berman P W, Huang W, Riddle L, Gray A M, Wrin T, Vennari J, Johnson A, Klaussen M, Prashad H, Köhne C, deWit C, Gregory T J
Abstract excerpt
Recombinant envelope glycoproteins prepared from a subtype B (MN) strain and a subtype E (CM244) strain of HIV-1 were combined to create a bivalent vaccine (B/E) effective against viruses circulating in the United States and Asia. Combining the two antigens resulted in formulations that increased the breadth and potency of the inter-subtype neutralizing response. Antibodies to the bivalent vaccine formulation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.